Literature DB >> 17062972

Daily shock impedance measured by implantable cardioverter defibrillator is useful in the management of congestive heart failure.

Kohei Matsushita1, Toshiyuki Ishikawa, Shinichi Sumita, Tsukasa Kobayashi, Hideyuki Ogawa, Noriko Inoue, Katsumi Matsumoto, Minoru Taima, Ichirou Nakazawa, Teruyasu Sugano, Tomoaki Ishigami, Kazuaki Uchino, Satoshi Umemura.   

Abstract

BACKGROUND: Clinical data suggest that changes in intrathoracic impedance and fluid accumulation in the lung are inversely related. METHODS AND
RESULTS: Daily shock impedance (S-IMP) was evaluated in 29 patients in whom a Ventak Prizm 2 was implanted (61+/-14 years old). The mean follow-up period was 45+/-18 weeks, during which 6 patients had episodes of decompensated heart failure (DHF group) and the others did not (NHF group). There was no significant difference between the DHF group and NHF group in the mean value of the S-IMP (46.4 +/-3.3 vs 45.4+/-5.4 Omega). The range of S-IMP in individual patients in the DHF group was significantly greater than that in the NHF group (13.8+/-0.38 vs 7.0+/-3.1 Omega, p<0.0001). Mean weekly change of S-IMP in individual patients in the DHF group was significantly greater than that in the NHF group (1.583+/-0.630 vs 1.092+/-0.361 Omega, p<0.0176). When the cut-off value was set at >1.242 Omega, sensitivity was 100% and specificity was 69.6% for a diagnosis of DHF. There was a significant negative correlation between the percent increases in brain natriuretic peptide (BNP) and S-IMP (correlation coefficient: -0.775 p<0.0001) in the DHF group. There was an inverse relation between BNP and S-IMP.
CONCLUSIONS: Measurement of shock impedance may be useful in the management of congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17062972     DOI: 10.1253/circj.70.1462

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  2 in total

1.  Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization.

Authors:  Giovanni B Perego; Maurizio Landolina; Giuseppe Vergara; Maurizio Lunati; Gabriele Zanotto; Alessia Pappone; Gabriele Lonardi; Giancarlo Speca; Saverio Iacopino; Annamaria Varbaro; Shantanu Sarkar; Doug A Hettrick; Alessandra Denaro
Journal:  J Interv Card Electrophysiol       Date:  2008-09-23       Impact factor: 1.900

2.  Potential value of automated daily screening of cardiac resynchronization therapy defibrillator diagnostics for prediction of major cardiovascular events: results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy) study.

Authors:  Stefan Sack; Christian Michael Wende; Herbert Nägele; Amos Katz; Wolfgang Rudolf Bauer; Craig Scott Barr; Klaus Malinowski; Harald Schwacke; Francisco Leyva; Jochen Proff; Sergey Berdyshev; Vincent Paul
Journal:  Eur J Heart Fail       Date:  2011-09       Impact factor: 15.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.